NCOA2-ARFGEF1 Fusion FISH Probe
The NCOA2-ARFGEF1 Fusion FISH Probe is used to confirm a fusion of the NCOA2 and ARFGEF1 genes. The fusion of the NCOA2 and ARFGEF1 genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| NCOA2-ARFGEF1-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-RERE | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-REOR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-REGO | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-REGR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-OROR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GORE | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GROR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| NCOA2-ARFGEF1-20-AQAQ | 20 (40 μL) | 200 μL |
|
NCOA2 Gene Summary
The protein encoded by this gene functions as a transcriptional coactivator for nuclear hormone receptors, including steroid, thyroid, retinoid, and vitamin D receptors. The encoded protein acts as an intermediary factor for the ligand-dependent activity of these nuclear receptors, which regulate their target genes upon binding of cognate response elements. This gene has been found to be involved in translocations that result in fusions with other genes in various cancers, including the lysine acetyltransferase 6A (KAT6A) gene in acute myeloid leukemia, the ETS variant 6 (ETV6) gene in acute lymphoblastic leukemia, and the hes related family bHLH transcription factor with YRPW motif 1 (HEY1) gene in mesenchymal chondrosarcoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016]
Gene Name: Nuclear Receptor Coactivator 2
Chromosome: CHR8: 71024266 -71316020
Locus: 8q13.3
ARFGEF1 Gene Summary
ADP-ribosylation factors (ARFs) play an important role in intracellular vesicular trafficking. The protein encoded by this gene is involved in the activation of ARFs by accelerating replacement of bound GDP with GTP. It contains a Sec7 domain, which may be responsible for guanine-nucleotide exchange activity and also brefeldin A inhibition. [provided by RefSeq, Aug 2011]
Gene Name: ADP Ribosylation Factor Guanine Nucleotide Exchange Factor 1
Chromosome: CHR8: 68109883 -68255912
Locus: 8q13.2
Gene Diseases
The NCOA2 ARFGEF1 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|